YOLFTbeta
Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

KPTI · NASDAQ · Healthcare / Biotechnology

0.0174USD-0.02 (-56.50%)

Price History

Full chart

Market Stats

Previous Close0.04
Open0.0295
Day Range0.017 – 0.0299
52-Week Range1.24 – 10.99
Volume136.65M
Market Cap36.74M
P/E (TTM)0.00
Forward P/E0.00
EPS-14.33
Dividend Yield0.00%
Beta0.95
50-Day Avg2.82
200-Day Avg6.83

About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Richard A. Paulson M.B.A.
  • Employees228
  • Headquarters85 Wells Avenue, Newton, MA, United States, 02459-3298, USA
  • Websitehttps://www.karyopharm.com

Leadership

  • Mr. Richard A. Paulson M.B.A.President, CEO & Director · b. 1967
  • Mr. Stuart PoultonExecutive VP & Chief Development Officer · b. 1973
  • Dr. Reshma Rangwala M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Research · b. 1978
  • Dr. Sharon Shacham M.B.A., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · b. 1970
  • Ms. Lori A. Macomber CPAEVP, CFO & Treasurer · b. 1971
  • Ms. Kristin AbateVP, Chief Accounting Officer & Assistant Treasurer
  • Mr. Brendan Twohig StrongSenior Vice President of Investor Relations
  • Mr. Michael J. Mano J.D.Executive VP, Chief Legal Officer & Secretary · b. 1977
  • Mr. James Accumanno J.D.Chief Compliance Officer
  • Ms. Lisa DiPaoloExecutive VP & Chief Human Resource Officer

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue152.00K634.00K387.00K229.00K250.00K154.00K1.60M30.34M40.89M108.08M209.82M157.07M146.03M145.24M146.07M
Growth (%)-+317.11%-38.96%-40.83%+9.17%-38.40%+942.21%+1790.09%+34.80%+164.31%+94.12%-25.14%-7.03%-0.55%+0.57%
Cost of Revenue10.38M14.10M34.19M60.13M97.74M86.94M107.27M161.37M2.41M2.71M3.40M5.21M4.94M6.01M5.95M
Gross Profit152.00K-13.46M387.00K-59.90M250.00K154.00K1.60M-131.04M38.49M105.38M206.42M151.86M141.09M139.23M140.12M
Gross Margin100.00%-2123.19%100.00%-26156.33%100.00%100.00%100.00%-431.95%94.11%97.50%98.38%96.68%96.62%95.86%95.93%
Operating Expense10.46M2.43M34.34M15.95M119.33M110.89M132.14M48.85M227.76M277.23M304.69M294.06M270.63M258.67M230.82M
Operating Income-10.31M-15.89M-33.95M-75.85M-119.08M-110.73M-130.54M-179.88M-189.28M-171.85M-98.27M-142.20M-129.54M-119.44M-90.71M
Operating Margin-6783.55%-2506.31%-8772.61%-33120.52%-47630.40%-71903.90%-8133.21%-592.97%-462.85%-159.00%-46.84%-90.53%-88.71%-82.24%-62.10%
EBITDA-10.23M-15.77M-33.81M-75.45M-118.44M-110.02M-129.82M-175.15M-182.93M-167.85M-96.98M-139.31M-118.42M-38.60M-149.85M
EBITDA Margin-6728.95%-2486.75%-8735.40%-32949.34%-47376.80%-71438.31%-8088.79%-577.38%-447.34%-155.30%-46.22%-88.69%-81.09%-26.58%-102.59%
Net Income-10.31M-15.89M-33.95M-75.78M-118.18M-109.58M-128.98M-178.41M-199.59M-196.27M-124.09M-165.29M-143.10M-76.42M-196.04M
Net Income Margin-6783.55%-2505.99%-8771.83%-33090.39%-47272.40%-71153.90%-8036.39%-588.10%-488.08%-181.59%-59.14%-105.23%-97.99%-52.62%-134.21%
R&D8.62M14.10M28.45M60.13M97.74M86.94M107.27M161.37M122.34M150.81M160.84M148.66M138.75M143.23M125.62M
R&D as % of Total Revenue5673.03%2223.19%7351.94%26256.33%39097.60%56453.25%6683.68%531.95%299.17%139.53%76.66%94.64%95.01%98.62%86.00%
Interest Expense02.00K3.00K1.00K895.00K1.29M1.62M2.49M15.65M27.14M26.05M25.00M23.82M37.42M45.85M
Interest Expense % of Total Revenue0.00%0.32%0.78%0.44%358.00%840.26%100.75%8.22%38.26%25.11%12.41%15.91%16.31%25.77%31.39%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.22M1.31M158.23M220.34M215.44M180.38M180.29M341.19M294.96M313.05M305.31M358.17M240.44M164.42M108.42M
Total Liabilities19.88M29.19M3.29M13.54M17.08M18.14M50.83M158.02M245.19M262.50M384.98M374.83M376.64M350.44M401.34M
Total Equity-12.65M-27.88M154.93M206.79M198.37M162.24M129.46M183.17M49.77M50.55M-79.67M-16.66M-136.21M-186.02M-292.93M
Cash6.51M391.00K155.97M150.61M58.36M49.66M69.00M118.02M128.86M85.92M190.46M135.19M52.23M62.48M60.54M
Total Debt-------135.55M111.50M119.84M180.58M179.07M177.02M194.52M233.61M
Net Debt-6.51M-391.00K-155.97M-150.61M-58.36M-49.66M-69.00M-15.36M-19.00M32.01M-9.88M43.89M124.78M132.05M173.07M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.55M-15.51M-30.29M-51.45M-94.03M-84.39M-73.72M-159.12M-190.82M-160.23M-107.12M-149.55M-92.72M-127.49M-75.37M
Investing Cash Flow-376.00K-121.00K-57.00K-67.03M-90.82M24.59M17.11M-107.66M78.45M-53.69M141.84M-104.26M7.94M95.47M43.38M
Financing Cash Flow11.99M9.51M185.93M113.12M92.70M51.16M75.74M316.11M124.31M172.08M73.65M193.74M1.12M41.65M30.05M
Capital Expenditure376.00K121.00K57.00K2.83M1.42M70.00K62.00K2.36M206.00K145.00K5.71M118.00K0142.00K0
Free Cash Flow-8.93M-15.63M-30.35M-54.28M-95.44M-84.46M-73.78M-161.48M-191.03M-160.38M-112.83M-149.67M-92.72M-127.63M-75.37M
Dividends Paid--00000--------
FCF to OCF104.40%100.78%100.19%105.51%101.51%100.08%100.08%101.49%100.11%100.09%105.33%100.08%100.00%100.11%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateNov 27, 2013Mar 5, 2014May 7, 2014Aug 7, 2014Nov 10, 2014Mar 11, 2015May 11, 2015Aug 10, 2015Nov 9, 2015Mar 14, 2016May 9, 2016Aug 4, 2016Nov 7, 2016Mar 16, 2017May 4, 2017Aug 8, 2017Nov 2, 2017Mar 15, 2018May 10, 2018Aug 7, 2018Nov 8, 2018Feb 28, 2019May 9, 2019Aug 6, 2019Nov 4, 2019Feb 13, 2020May 5, 2020Aug 4, 2020Nov 2, 2020Feb 11, 2021May 3, 2021Aug 5, 2021Nov 3, 2021Feb 8, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Feb 15, 2023May 4, 2023Aug 2, 2023Nov 2, 2023Feb 29, 2024May 8, 2024Aug 6, 2024Nov 5, 2024Feb 19, 2025May 12, 2025Aug 11, 2025Nov 3, 2025Feb 12, 2026May 14, 2026Aug 13, 2026Nov 2, 2026
EPS Estimate--6.82-8.65-7.10-6.50-0.65-11.95-10.77-12.91-0.82-10.80-10.85-11.65-0.66-9.59-9.77-9.45-0.65-9.62-12.03-13.15-0.85-12.89-14.29-12.17-10.16-10.29-8.92-10.48-8.97-10.75-10.97-10.27-6.37-9.24-9.55-8.02-5.38-5.23-5.04-4.29-0.31-4.94-4.47-3.92-4.03-3.09-3.91-3.25-2.00-1.44-1.53-1.15
EPS Actual-4.70-6.60-6.90-8.25-9.15-0.79-11.10-13.80-12.75-0.81-11.25-12.60-10.35-0.65-10.65-9.60-9.75-0.80-11.70-9.00-11.85-0.96-16.35-10.65-10.05-11.40-11.70-9.45-10.95-8.85-11.55-10.65-10.356.90-7.95-9.30-6.75-6.45-4.50-4.35-4.50-0.36-4.80-4.34-3.90-3.60-2.77-4.07-3.82-2.23-1.24-2.32-
Surprise-3.23%20.23%-16.20%-40.77%-21.54%7.11%-28.13%1.24%1.22%-4.17%-16.13%11.16%1.52%-11.05%1.74%-3.17%-23.08%-21.62%25.19%9.89%-12.94%-26.84%25.47%17.42%-12.20%-13.70%-5.94%-4.48%1.34%-7.44%2.92%-0.78%208.32%13.96%2.62%15.84%-19.89%13.96%13.69%-4.90%-16.13%2.83%2.91%0.51%10.67%10.36%-4.09%-17.54%-11.50%13.89%-51.63%-
Timing-Pre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap36.74M
Enterprise Value230.89M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio-0.15
Price / Sales0.25
Price / Book12.05
EPS-14.33
Book Value-14.56
Revenue (TTM)146.62M
Gross Profit (TTM)145.25M
EBITDA-82.20M
Profit Margin-153.28%
Operating Margin-67.38%
Return on Equity-891.05%
Return on Assets-47.61%
Shares Outstanding22.68M
Shares Float16.01M
Beta0.95
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 7.25
  • Strong Buy
    4
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
98.09%
Insiders
4.67%
Retail / Other
0.00%

Top Institutional Holders

  • COMMODORE CAPITAL LP
    1.95M8.60%
  • RA Capital Management, LLC
    1.92M8.45%
  • T. Rowe Price Investment Management,Inc.
    1.54M6.80%
  • Adage Capital Partners Gp LLC
    1.52M6.71%
  • The Goldman Sachs Group Inc
    947.58K4.18%
  • Catalio Capital Management, LP
    940.86K4.15%
  • Avidity Partners Management LP
    924.49K4.08%
  • Vanguard Capital Management, LLC
    739.75K3.26%
  • Ikarian Capital, LLC
    733.43K3.23%
  • Two Sigma Investments LLC
    695.26K3.07%
  • Soleus Capital Management, L.P.
    440.00K1.94%
  • Affinity Asset Advisors, LLC
    312.50K1.38%
  • Millennium Management LLC
    305.68K1.35%
  • Boxer Capital Management, LLC
    302.54K1.33%
  • Davidson Kempner Capital Management LP
    300.00K1.32%
  • Eversept Partners, LP
    276.17K1.22%
  • Jump Financial LLC
    262.15K1.16%
  • Trexquant Investment LP
    257.90K1.14%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    677.73K2.99%
  • iShares Russell 2000 ETF
    482.93K2.13%

Stock Splits

  • Feb 26, 20251:15